Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm

In an era where conventional treatment for pancreatic ductal adenocarcinoma (PDAC) using surgery and chemotherapy-based adjuvant modalities are associated with limited efficacy, significant toxicity and drug resistance, a shift in treatment paradigms is warranted to meet this major unmet clinical need. PDAC represents the 3rd leading cause of cancer death with a current 5-year Overall Survival (OS) rate of 12  % highlighting the need for development of new treatment approaches [1]. Such patients often present with locally advanced or metastatic disease by virtue of anatomy involving superior mesenteric arteries and veins which limits their outcomes associated with the current treatment paradigm.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research